Johnson & Johnson turned in a solid first quarter Tuesday, topping analysts' profit and revenue estimates and increasing its 2014 earnings forecast by 5 cents a share.» Read More
Using a technology that echoes science fiction, a company is offering people a place to store their stem cells in a bet that they may one day be used to grow replacement organs.
Transplant experts will meet to decide whether and how to change the rules for children, after the parents of two youngsters successfully sued to get restrictions temporarily lifted.
Time to begin picking through the rubble, looking for stocks that have already been crushed, Cramer said.
Bristol-Myers Squibb and Merck stocks climbed higher Monday as analysts said billions stood to be made from treatment breakthroughs.
Americans accustomed to immediate access to the newest technology may be shocked to find that is not the case when it comes to devices that treat ailing hearts.
Peter Wilmshurst, Portfolio Manager, Templeton Global Equity Group at Franklin Templeton Investments tells CNBC's Cash Flow why he likes pharmaceutical stocks at the moment.
The health-care industry is looking to harness big data, but finding the right workers isn't always easy. In some cases, companies are making acquisitions to bring talent in-house.
A team of oncologists from Sloan-Kettering have been working with IBM's Watson programmers and engineers to train the system to understand cancer treatment in the hopes of providing better care.
John Sculley, Former Apple CEO, Former PepsiCo President, and Partner at Sculley Brothers says Apple is still a strong player in the tech arena. He also sheds light on what could be the next big innovation from the technology and healthcare space.
Keith Smith, Co-founder, Managing Partner at the Surgery Center of Oklahoma says that all funds are channeled to patient care, helping his team deliver quality healthcare and low costs.
The rise of "superbugs," and pressure from the government and insurers, is driving hospitals to try all sorts of new approaches to stop their spread.
In recent years, as the surgical robot's popularity has grown, so have questions and concerns about its safety, training and the aggressiveness of its marketing.
Irish drugmaker Elan has sweetened the terms on offer to shareholders under its $3.25 billion disposal plan, as it aims to stave off an approach for the company from U.S. investment firm Royalty Pharma.
A sharp and surprisingly persistent slowdown in the growth of health care costs is helping to narrow the federal deficit, leaving budget experts trying to figure out whether the trend will last.
Pfizer's unit Zoetis plans to sell 86.1 million shares at between $22 and $25 each in an initial public offering.
Eli Lilly will be "very challenged" by the loss of exclusivity on several blockbuster drugs, CEO John Lechleiter told CNBC on Tuesday, but added the company can manage its growth in response.
States are setting up health insurance exchanges, reports CNBC's Bertha Coombs. Max Nisen, Business Insider, also weighs in.
It's hard to see how lawmakers can avoid touching health insurance if they want to eliminate loopholes and curtail deductions so as to raise revenue and lower tax rates.
DaVita could be a beneficiary among health care stocks from changes in the U.S. health care market, an analyst said Wednesday.
While Silicon Valley and other traditional high-tech hubs claim dominance as places for startups, demand for health care and other business services has put places like Indianapolis and Salt Lake City on the entrepreneurial map.